A number of research analysts recently issued reports on FENC shares. Stephens upgraded Fennec Pharmaceuticals to a “strong-buy” rating in a research report on Monday, November 18th.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback